Shanghai Henlius Biotech’s HLX02, a trastuzumab biosimilar, achieved similar overall response rates (ORR) to reference trastuzumab (Herceptin®; Roche) in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic...